Navigation Links
Sangart, Inc. Completes Series F Funding Round
Date:3/12/2009

SAN DIEGO, March 12 /PRNewswire/ -- Sangart, Inc., a privately held biopharmaceutical company focused on the research, development and commercialization of oxygen therapeutics, today announced the receipt of approximately $50 million in funding from existing investors. This investment results from the exercise of warrants issued by Sangart as part of a Series F financing round initiated in 2007. The most recent investment brings the total funding under the Series F round to approximately $100 million. Proceeds from this warrant exercise will be used to fund further clinical development of Sangart's MP4 oxygen therapeutic products.

"We are excited to see this continued support from our investors and believe it demonstrates the potential of our products," said Brian O'Callaghan, President and CEO of Sangart. "This funding contributes significantly to our efforts to further the clinical research and development of our MP4 oxygen therapeutic products."

About MP4 Oxygen Therapeutics

The MP4 molecule is the basis for Sangart's oxygen therapeutic product platform. The MP4 molecule is created using unique polyethylene glycol conjugation with human hemoglobin and was specifically designed to the optimal molecular size, viscosity, oxygen affinity and diffusion potential to target oxygen delivery to tissues at risk of oxygen deprivation based on experiments with artificial capillaries and in several different animal models. Extensive research and testing demonstrates that this approach optimizes oxygen delivery while minimizing the side effects that plagued earlier generation products.

About Sangart

Sangart, Inc. is a privately held biopharmaceutical company focused on being the global scientific, clinical and commercial leader in oxygen-therapeutic agents, providing innovative products to patients in need. Sangart was founded based on technologies developed during more than two deca
'/>"/>

SOURCE Sangart, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sangart, Inc. Announces Key Executive Appointments and Company Restructuring
2. Sangart, Inc. Completes Enrollment in Second Phase III Study of Hemospan, a Novel Oxygen Transport Agent
3. Cardium Completes $3.5 Million Credit Facility
4. Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company
5. Enobia Completes Target Enrollment in Clinical Trial for Infantile Hypophosphatasia
6. CIRM Completes Briefing Visit to Stemedica Cell Technologies
7. INVO Bioscience Completes Reverse Merger
8. Particle Sciences Completes Development of First Product Incorporating its Unique Surface Modification System
9. Mach One Corporation Completes Acquisition of Ceres Organic Harvest, Inc.
10. Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Indevus Pharmaceuticals and Announces Subsequent Offering Period
11. New Generation Biofuels Completes Construction of Baltimore Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... LA JOLLA, Calif. , April 21, 2015 ... (JCVI), a not-for-profit genomic research organization, published a ... manipulate a type of microalgae called diatoms. The ... , Ph.D. and senior author Philip Weyman ... methods will enable better understanding of diatom genetics ...
(Date:4/21/2015)... , April 21, 2015 Merrimack Pharmaceuticals, Inc. (Nasdaq: ... a multi-arm Phase 1 study of MM-141, a bispecific ... in an oral session by Dr. Mansoor Saleh ... Research Annual Meeting in Philadelphia, PA. ... MM-141 as a monotherapy and in combination with everolimus ...
(Date:4/21/2015)... ENGLEWOOD, Colo. , April 21, 2015 ... details for a scheduled investor call on Thursday, April ... in using the instructions as follows: ... toll-free number: (844) 789-4877 International toll number: (925) ... emailed in advance to Tina Amirkiai , ...
(Date:4/21/2015)... FOREST, Calif. , April 21, 2015 ... leading provider of advanced cryogenic logistics solutions ... including immunotherapies, stem cells, cell lines, clinical ... today announced that Dr. Mark W. ... at the 3rd Annual BioLogistics Summit in ...
Breaking Biology Technology:Scientists at the J. Craig Venter Institute Publish Paper Outlining Efficient Synthetic Biology Methods to Genetically Engineer Microalgae 2Scientists at the J. Craig Venter Institute Publish Paper Outlining Efficient Synthetic Biology Methods to Genetically Engineer Microalgae 3First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 2First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 3First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 4First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 5Ampio Announces Investor Call on Thursday, April 23, 4:30 p.m. ET 2Cryoport to Present at the 3rd Annual BioLogistics Summit in San Francisco, CA 2Cryoport to Present at the 3rd Annual BioLogistics Summit in San Francisco, CA 3
... Inc. (Amex: IMA ), a leading manufacturer ... and professional markets, announced,today that it will attend ... Conference being held May 28, 2008 at the ... Management, and Jon Russell, Vice,President, Finance, will attend. ...
... , - Production Increase Brings Large Disease ... AMT), a leader in the field,of human gene ... and Development Agreement from the National Heart, Lung, ... Health (NIH), Bethesda,Maryland, that promises to substantially enhance ...
... Screening and Treatment, and an Apparent Higher Prevalence ... Than in North America and Australia, BARCELONA, Spain, May ... women surveyed from Europe, North America, and,Australia reported having one ... women considered to be at high risk for a fracture, ...
Cached Biology Technology:Inverness Medical Innovations to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 28, 2008 2AMT's Cooperative Research and Development Agreement With NIH to Boost Production Capacity 2AMT's Cooperative Research and Development Agreement With NIH to Boost Production Capacity 3Global Study Reveals Differences in Standard of Care for Osteoporosis Across the World 2Global Study Reveals Differences in Standard of Care for Osteoporosis Across the World 3Global Study Reveals Differences in Standard of Care for Osteoporosis Across the World 4
(Date:3/23/2015)... SoundView Technology Group issues a new research update following the ... wallet. SoundView was one of the selected user groups to provide ... in multiple scenarios and outlets. Soundview shares ... both debit and credit card payments.  Soundview ... meets their plans in 2015, it would push our IV ...
(Date:3/20/2015)... DUBLIN , Mar. 20, 2015 Research ... announced the addition of the "India Sensors ... their offering. The sensor market is ... through 2020 Consumer electronics, automotive, industrial ... for sensors in the country. In addition, adoption ...
(Date:3/19/2015)... , March 19, 2015  NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces its ... a news clip that aired this week on ... . In a segment "The Next Great Thing", ... ,a new way to pay, and ,a really big breakthrough ...
Breaking Biology News(10 mins):Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3
... threatened? Hungry? Looking for a mate? Move! Tracking and remote ... find out what they are up to. However, general theories ... Ecology in the journal Proceedings of the National Academy ... organisms as diverse as gut bacteria, tree seeds, ants, marine ...
... in French . Plant researchers ... have announced a major breakthrough in a developmental process ... the reversal of what is called epigenetic silencing in ... a better understanding of gene regulation in the continuing ...
... sedentary lifestyles and filter-feeding habits, clams have been silent ... their waters. These clams are silent no more, ... Sea Lab and her colleagues have reported in their ... . Using stable isotope techniques, Carmichael demonstrated it ...
Cached Biology News:New movement models tested at the Smithsonian in Panama 2Plants display 'molecular amnesia' 2Plants display 'molecular amnesia' 3
... Immunogen KLH-conjugated, synthetic ... 54-75 (RRGPHRNPG-PGDDDGQRSRSSS) of mouse p19ARF. ... to amino acids 62-75. Clone ... Routinely evaluated by immunoblot. ...
EDG-1 Western blot control Source: Cell Lysate Application: Western Blotting Control...
Complete cell culture media with cytokines...
...
Biology Products: